Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 5, 2006, Pages 442-447

  Thompson, R Houston ^a   Allison, James P ^b   Kwon, Eugene D ^a,c  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Costimulation; CTLA 4; Immunotherapy; Prostatic neoplasms; T lymphocyte

Indexed keywords

CTLA 4 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MONOCLONAL ANTIBODY; RITUXIMAB; STEROID; T LYMPHOCYTE RECEPTOR; TRASTIZUMAB; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG POTENCY; DRUG TOLERABILITY; ENTEROCOLITIS; GENETIC ENGINEERING; HEPATITIS; HUMAN; HYPOPHYSITIS; LARGE CELL LYMPHOMA; MELANOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

EID: 33748171465     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.08.011     Document Type: Review

References (43)

1. Mueller D.L., Jenkins M.K., and Schwartz R.H. Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 7 (1989) 445-480
2. Chambers C.A., Kuhns M.S., Egen J.G., et al. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19 (2001) 565-594
3. Schwartz R.H. T cell anergy. Annu Rev Immunol 21 (2003) 305-334
4. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4 (2004) 336-347
5. Frauwirth K.A., and Thompson C.B. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 109 (2002) 295-299
6. Shahinian A., Pfeffer K., Lee K.P., et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261 (1993) 609-612
7. Borriello F., Sethna M.P., Boyd S.D., et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity 6 (1997) 303-313
8. Weinberg A.D., Rivera M.M., Prell R., et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164 (2000) 2160-2169
9. Gramaglia I., Weinberg A.D., Lemon M., et al. Ox-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 161 (1998) 6510-6517
10. Cheuk A.T., Mufti G.J., and Guinn B.A. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther 11 (2004) 215-226
11. Thompson C.B., and Allison J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity 7 (1997) 445-450
12. Chambers C.A., Cado D., Truong T., et al. Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci USA 94 (1997) 9296-9301
13. Tivol E.A., Borriello F., Schweitzer A.N., et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 (1995) 541-547
14. Waterhouse P., Penninger J.M., Timms E., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270 (1995) 985-988
15. Mandelbrot D.A., McAdam A.J., and Sharpe A.H. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J Exp Med 189 (1999) 435-440
16. Krummel M.F., Sullivan T.J., and Allison J.P. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol 8 (1996) 519-523
17. Chen W., Jin W., and Wahl S.M. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med 188 (1998) 1849-1857
18. Krummel M.F., and Allison J.P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183 (1996) 2533-2540
19. Brunner M.C., Chambers C.A., Chan F.K., et al. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 162 (1999) 5813-5820
20. Read S., Malmstrom V., and Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192 (2000) 295-302
21. Takahashi T., Tagami T., Yamazaki S., et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192 (2000) 303-310
22. Salomon B., Lenschow D.J., Rhee L., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12 (2000) 431-440
23. Grohmann U., Orabona C., Fallarino F., et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3 (2002) 1097-1101
24. Fallarino F., Grohmann U., Vacca C., et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 9 (2002) 1069-1077
25. Fallarino F., Grohmann U., Hwang K.W., et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4 (2003) 1206-1212
26. Liu B., Podack E.R., Allison J.P., et al. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J Immunol 156 (1996) 1117-1125
27. Greenberg N.M., DeMayo F., Finegold M.J., et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92 (1995) 3439-3443
28. Kwon E.D., Hurwitz A.A., Foster B.A., et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 94 (1997) 8099-8103
29. Kwon E.D., Foster B.A., Hurwitz A.A., et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA 96 (1999) 15074-15079
30. Hurwitz A.A., Foster B.A., Kwon E.D., et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60 (2000) 2444-2448
31. Leach D.R., Krummel M.F., and Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 (1996) 1734-1736
32. Yang Y.F., Zou J.P., Mu J., et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages. Cancer Res 57 (1997) 4036-4041
33. Hurwitz A.A., Yu T.F., Leach D.R., et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 95 (1998) 10067-10071
34. van Elsas A., Hurwitz A.A., and Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190 (1999) 355-366
35. Perrin P.J., Maldonado J.H., Davis T.A., et al. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 157 (1996) 1333-1336
36. Luhder F., Hoglund P., Allison J.P., et al. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 187 (1998) 427-432
37. Keler T., Halk E., Vitale L., et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol 171 (2003) 6251-6259
38. Hanahan D., Lanzavecchia A., and Mihich E. Fourteenth Annual Pezcoller Symposium: The novel dichotomy of immune interactions with tumors. Cancer Res 63 (2003) 3005-3008
39. Hodi F.S., Mihm M.C., Soiffer R.J., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100 (2003) 4712-4717
40. Krejci K.G., Markiewicz M.A., and Kwon E.D. Immunotherapy for urological malignancies. J Urol 171 (2004) 870-876
41. Phan G.Q., Yang J.C., Sherry R.M., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100 (2003) 8372-8377
42. Sanderson K., Scotland R., Lee P., et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23 (2005) 741-750
43. Mercader M., Bodner B.K., Moser M.T., et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 98 (2001) 14565-14570